Jonggi Choi1, Hassan M Ghoz1, Thoetchai Peeraphatdit1,2, Esha Baichoo1,3, Benyam D Addissie1, William S Harmsen4, Terry M Therneau4, Janet E Olson5, Roongruedee Chaiteerakij1,6, Lewis R Roberts1. 1. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA. 2. Department of Internal Medicine, University of Minnesota, Minneapolis, MN, USA. 3. Department of Medicine, Mount Sinai Roosevelt Hospital, New York, NY. 4. Department of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA. 5. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 6. Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Abstract
UNLABELLED: Whether aspirin use is protective against cholangiocarcinoma (CCA) remains unclear. We determined the association between aspirin use and other risk factors for each CCA subtype individually. In a hospital-based case-control study, 2395 CCA cases (1169 intrahepatic, 995 perihilar, and 231 distal) seen at the Mayo Clinic, Rochester, MN, from 2000 through 2014 were enrolled. Controls selected from the Mayo Clinic Biobank were matched two to one with cases by age, sex, race, and residence (n = 4769). Associations between aspirin use, other risk factors, and CCA risk were determined. Aspirin was used by 591 (24.7%) CCA cases and 2129 (44.6%) controls. There was a significant inverse association of aspirin use with all CCA subtypes, with adjusted odds ratios (AORs) of 0.35 (95% confidence interval [CI], 0.29-0.42), 0.34 (95% CI 0.27-0.42), and 0.29 (95% CI 0.19-0.44) for intrahepatic, perihilar, and distal CCA, respectively (P < 0.001 for all). Primary sclerosing cholangitis was more strongly associated with perihilar (AOR = 453, 95% CI 104-999) than intrahepatic (AOR = 93.4, 95% CI 27.1-322) or distal (AOR = 34.0, 95% CI 3.6-323) CCA, whereas diabetes was more associated with distal (AOR = 4.2, 95% CI 2.5-7.0) than perihilar (AOR = 2.9, 95% CI 2.2-3.8) or intrahepatic (AOR = 2.5, 95% CI 2.0-3.2) CCA. Cirrhosis not related to primary sclerosing cholangitis was associated with both intrahepatic and perihilar CCA, with similar AORs of 14. Isolated inflammatory bowel disease without primary sclerosing cholangitis was not associated with any CCA subtype. CONCLUSIONS: Aspirin use was significantly associated with a 2.7-fold to 3.6-fold decreased risk for the three CCA subtypes; our study demonstrates that individual risk factors confer risk of different CCA subtypes to different extents. (Hepatology 2016;64:785-796).
UNLABELLED: Whether aspirin use is protective against cholangiocarcinoma (CCA) remains unclear. We determined the association between aspirin use and other risk factors for each CCA subtype individually. In a hospital-based case-control study, 2395 CCA cases (1169 intrahepatic, 995 perihilar, and 231 distal) seen at the Mayo Clinic, Rochester, MN, from 2000 through 2014 were enrolled. Controls selected from the Mayo Clinic Biobank were matched two to one with cases by age, sex, race, and residence (n = 4769). Associations between aspirin use, other risk factors, and CCA risk were determined. Aspirin was used by 591 (24.7%) CCA cases and 2129 (44.6%) controls. There was a significant inverse association of aspirin use with all CCA subtypes, with adjusted odds ratios (AORs) of 0.35 (95% confidence interval [CI], 0.29-0.42), 0.34 (95% CI 0.27-0.42), and 0.29 (95% CI 0.19-0.44) for intrahepatic, perihilar, and distal CCA, respectively (P < 0.001 for all). Primary sclerosing cholangitis was more strongly associated with perihilar (AOR = 453, 95% CI 104-999) than intrahepatic (AOR = 93.4, 95% CI 27.1-322) or distal (AOR = 34.0, 95% CI 3.6-323) CCA, whereas diabetes was more associated with distal (AOR = 4.2, 95% CI 2.5-7.0) than perihilar (AOR = 2.9, 95% CI 2.2-3.8) or intrahepatic (AOR = 2.5, 95% CI 2.0-3.2) CCA. Cirrhosis not related to primary sclerosing cholangitis was associated with both intrahepatic and perihilar CCA, with similar AORs of 14. Isolated inflammatory bowel disease without primary sclerosing cholangitis was not associated with any CCA subtype. CONCLUSIONS:Aspirin use was significantly associated with a 2.7-fold to 3.6-fold decreased risk for the three CCA subtypes; our study demonstrates that individual risk factors confer risk of different CCA subtypes to different extents. (Hepatology 2016;64:785-796).
Authors: Enju Liu; Lori C Sakoda; Yu-Tang Gao; Asif Rashid; Ming-Chang Shen; Bing-Sheng Wang; Jie Deng; Tian-Quan Han; Bai-He Zhang; Joseph F Fraumeni; Ann W Hsing Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-05 Impact factor: 4.254
Authors: N Hayashi; H Yamamoto; N Hiraoka; K Dono; Y Ito; J Okami; M Kondo; H Nagano; K Umeshita; M Sakon; N Matsuura; S Nakamori; M Monden Journal: Hepatology Date: 2001-10 Impact factor: 17.425
Authors: Michael Pignone; George K Anderson; Katherine Binns; Hugh H Tilson; Steven M Weisman Journal: Am J Prev Med Date: 2007-05 Impact factor: 5.043
Authors: Peter M Rothwell; F Gerald R Fowkes; Jill F F Belch; Hisao Ogawa; Charles P Warlow; Tom W Meade Journal: Lancet Date: 2010-12-06 Impact factor: 79.321
Authors: Luke Boulter; Rachel V Guest; Timothy J Kendall; David H Wilson; Davina Wojtacha; Andrew J Robson; Rachel A Ridgway; Kay Samuel; Nico Van Rooijen; Simon T Barry; Stephen J Wigmore; Owen J Sansom; Stuart J Forbes Journal: J Clin Invest Date: 2015-02-17 Impact factor: 14.808
Authors: Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores Journal: Nat Rev Gastroenterol Hepatol Date: 2020-06-30 Impact factor: 46.802
Authors: Jessica L Petrick; Jake E Thistle; Anne Zeleniuch-Jacquotte; Xuehong Zhang; Jean Wactawski-Wende; Alison L Van Dyke; Meir J Stampfer; Rashmi Sinha; Howard D Sesso; Catherine Schairer; Lynn Rosenberg; Thomas E Rohan; Kim Robien; Mark P Purdue; Jenny N Poynter; Julie R Palmer; Christina C Newton; Martha S Linet; Linda M Liao; I-Min Lee; Jill Koshiol; Cari M Kitahara; Jonathan N Hofmann; Barry I Graubard; Edward Giovannucci; Michael J Gaziano; Susan M Gapstur; Neal D Freedman; Dawn Q Chong; Andrew T Chan; Julie E Buring; Laura Beane E Freeman; Peter T Campbell; Katherine A McGlynn Journal: Am J Gastroenterol Date: 2018-09-03 Impact factor: 10.864
Authors: Lewis R Roberts; Nele Brusselaers; Lorena Marcano-Bonilla; Cathy D Schleck; William S Harmsen; Omid Sadr-Azodi; Mitesh J Borad; Tushar Patel; Gloria M Petersen; Terry M Therneau Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-04-01 Impact factor: 4.090